Literature DB >> 22830353

Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray.

Mitra Mehrazma1, Zahra Madjd, Elham Kalantari, Mahshid Panahi, Alireza Hendi, Ahmad Shariftabrizi.   

Abstract

Based on the cancer stem cell (CSC) concept model, a small population of cells with unique self-renewal properties and malignant potential exists in tumors. Immunohistochemistry was performed to detect the expression of CSC markers, CD133 and CD44, in a series of pediatric tumors. The association between expression of these markers and tumor characteristics was then analyzed. In Wilms tumors (WT), a significant positive correlation was found between expression of CD133 and the National Wilms Tumor Stage (NWTS) (p = 0.047). In neuroblastomas (NB), expression of CD133 was positively correlated with the International Neuroblastoma Staging System (INSS) (p-value = 0.012), indicating that the rate of CD133 positivity increased with the stage of these tumors. CD133, as a putative stem cell marker, is associated with more advanced stages of Wilms and NB tumors; therefore, this molecule can be a potential clinical prognostic marker in children suffering from NB or Wilms tumor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22830353     DOI: 10.3109/15513815.2012.701266

Source DB:  PubMed          Journal:  Fetal Pediatr Pathol        ISSN: 1551-3815            Impact factor:   0.958


  10 in total

1.  Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.

Authors:  Elham Kalantari; Mojgan Asgari; Seyedehmoozhan Nikpanah; Naghme Salarieh; Mohammad Hossein Asadi Lari; Zahra Madjd
Journal:  Pathol Oncol Res       Date:  2017-01-12       Impact factor: 3.201

Review 2.  Strategies for isolating and enriching cancer stem cells: well begun is half done.

Authors:  Jiang-Jie Duan; Wen Qiu; Sen-Lin Xu; Bin Wang; Xian-Zong Ye; Yi-Fang Ping; Xia Zhang; Xiu-Wu Bian; Shi-Cang Yu
Journal:  Stem Cells Dev       Date:  2013-05-09       Impact factor: 3.272

3.  Suppression of STAT3 NH2 -terminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via de-repression by microRNA-21.

Authors:  Sutapa Ray; Don W Coulter; Shawn D Gray; Jason A Sughroue; Shrabasti Roychoudhury; Erin M McIntyre; Nagendra K Chaturvedi; Kishor K Bhakat; Shantaram S Joshi; Timothy R McGuire; John G Sharp
Journal:  Mol Carcinog       Date:  2018-01-25       Impact factor: 4.784

4.  Evaluation of CD133 and CD56/NCAM expression in Wilms tumor and their association with prognostic factors.

Authors:  Amir Hossein Jafarian; Nona Zabolinejad; Nema Mohamadian Roshan; Sara Hashemi; Masoumeh Gharib
Journal:  Iran J Basic Med Sci       Date:  2020-07       Impact factor: 2.699

5.  A comparative study of mesenchymal stem cell transplantation with its paracrine effect on control of hyperglycemia in type 1 diabetic rats.

Authors:  Ehsan Aali; Solmaz Mirzamohammadi; Habib Ghaznavi; Zahra Madjd; Bagher Larijani; Samira Rayegan; Ali M Sharifi
Journal:  J Diabetes Metab Disord       Date:  2014-08-11

Review 6.  Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.

Authors:  Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko
Journal:  J Immunol Res       Date:  2018-07-11       Impact factor: 4.818

Review 7.  Cancer Stem Cells in Neuroblastoma: Expanding the Therapeutic Frontier.

Authors:  Hisham F Bahmad; Farah Chamaa; Sahar Assi; Reda M Chalhoub; Tamara Abou-Antoun; Wassim Abou-Kheir
Journal:  Front Mol Neurosci       Date:  2019-05-27       Impact factor: 5.639

Review 8.  Ovarian cancer stem cells and targeted therapy.

Authors:  Vahideh Keyvani; Moein Farshchian; Seyed-Alireza Esmaeili; Hadi Yari; Meysam Moghbeli; Seyed-Reza Kazemi Nezhad; Mohammad Reza Abbaszadegan
Journal:  J Ovarian Res       Date:  2019-12-06       Impact factor: 4.234

Review 9.  Dodging the bullet: therapeutic resistance mechanisms in pediatric cancers.

Authors:  Nilay Shah
Journal:  Cancer Drug Resist       Date:  2019-09-19

10.  Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan.

Authors:  Nagendra K Chaturvedi; Timothy R McGuire; Don W Coulter; Ashima Shukla; Erin M McIntyre; John Graham Sharp; Shantaram S Joshi
Journal:  Oncotarget       Date:  2016-03-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.